YouTube video

Hagen Kennecke, MD, MHA, FRCPC: Cabozantinib as a Treatment Option Following Progression in NET

Dr. Hagen Kennecke discusses the use of cabozantinib in the treatment of patients with NET who progressed on prior therapies.

MORE Expert Perspectives in NET

Hagen Kennecke, MD, MHA, FRCPC: Benefit of Cabozantinib in Patients with Advanced Neuroendocrine Tumors

Hagen Kennecke, a medical oncologist and professor of medicine at Oregon Health Sciences University, discusses the efficacy of cabozantinib in patients with advanced neuroendocrine tumors, specifically in relation to progression-free survival.

Neena Vijayvergia, MD: Importance of Patient Education for Treating Neuroendocrine Tumors

Dr. Vijayvergia emphasizes the importance of patient-physician communication and patient education when treating neuroendocrine tumors.
Facebook Linkedin

©2026 Oncology Matrix. All Rights Reserved.